Anixa Biosciences, Inc.
Compare this stock
ANIX Stock Report Card
$
39%
Performance
Score:
10/100
ANIX returned -42.05% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
Analyst Price Targets
Score:
75/100
1 analysts offer 12-month price targets for ANIX. Together, they have an average target of 8, the most optimistic target put ANIX at 8 within 12-months and the most pessimistic has ANIX at 8.
Sentiment
Score:
67/100
ANIX had a bullish sentiment score of 66.58% across Twitter and StockTwits over the last 12 months. It had an average of 1.57 posts, 0.29 comments, and 1.43 likes per day.
Technicals
Score:
11/100
ANIX receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.
Earnings
Score:
61/100
ANIX has missed earnings 3 times in the last 20 quarters.
Profit
Score:
10/100
Out of the last 20 quarters, ANIX has had 0 profitable quarters and has increased their profits year over year on 0 of them.
Volatility
Score:
34/100
ANIX has had a lower than average amount of volatility over the last 12 months giving it a score of 34 of 100.
Anixa Biosciences, Inc. Summary
Nasdaq / ANIX
Healthcare
Biotechnology
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Checkout Similar Companies
ANIX scored poorly on our reportcard. Here are some similar companies and how they performed.
